- In late March 2026, Johnson & Johnson reported 52-week Phase 3 data showing its oral peptide ICOTYDE maintained high complete skin clearance rates and a consistent safety profile in adults and adolescents with moderate-to-severe plaque psoriasis, while Royalty Pharma announced a US$500 million R&D co-funding agreement to advance JNJ-4804 for autoimmune diseases.
- These developments highlight Johnson & Johnson’s push to build a differentiated immunology portfolio, pairing late-stage oral psoriasis data with external funding support for an early-stage co-antibody therapy targeting IL-23 and TNF pathways.
- We’ll now examine how ICOTYDE’s year-long psoriasis data reshapes Johnson & Johnson’s investment narrative around its Innovative Medicine pipeline.
The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 21 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.
Johnson & Johnson Investment Narrative Recap
To be a Johnson & Johnson shareholder today, you need to believe in its ability to refresh Innovative Medicine earnings as older blockbusters face biosimilar and pricing pressure. ICOTYDE’s strong 52 week psoriasis data and the US$500 million JNJ 4804 co funding help reinforce the immunology pipeline as a key near term catalyst, but they do not eliminate the broader risks around talc litigation and pricing reform that still matter to the equity story.
The Royalty Pharma co funding agreement around JNJ 4804 looks especially relevant here, because it pairs ICOTYDE’s late stage psoriasis profile with external support for an earlier autoimmune asset that also targets the IL 23 pathway. Together, these updates give more substance to Johnson & Johnson’s push in immunology, which sits alongside oncology and MedTech programs as important potential offsets to STELARA’s loss of exclusivity and ongoing orthopedics softness.
Yet in contrast, investors should still pay close attention to how talc litigation could affect...
Read the full narrative on Johnson & Johnson (it's free!)
Johnson & Johnson's narrative projects $112.7 billion revenue and $25.4 billion earnings by 2029. This requires 6.2% yearly revenue growth and a $1.4 billion earnings decrease from $26.8 billion today.
Uncover how Johnson & Johnson's forecasts yield a $241.08 fair value, in line with its current price.
Exploring Other Perspectives
Before this psoriasis update, the most optimistic analysts were already assuming J&J could reach about US$115.7 billion in revenue by 2029, which is a far more ambitious view than consensus and could look very different once you factor in ICOTYDE’s data and the added risk that pricing pressure on big immunology brands might build faster than expected.
Explore 13 other fair value estimates on Johnson & Johnson - why the stock might be worth 23% less than the current price!
Decide For Yourself
Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.
- A great starting point for your Johnson & Johnson research is our analysis highlighting 3 key rewards and 2 important warning signs that could impact your investment decision.
- Our free Johnson & Johnson research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Johnson & Johnson's overall financial health at a glance.
Contemplating Other Strategies?
Right now could be the best entry point. These picks are fresh from our daily scans. Don't delay:
- AI is about to change healthcare. These 37 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
- Uncover the next big thing with 33 elite penny stocks that balance risk and reward.
- The future of work is here. Discover the 33 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com